Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

Monday, Nov 17, 2025 7:17 am ET1min read
SABS--

Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet